Vertex director logs equity grants and share deferral
Vertex Pharmaceuticals director Suketu Upadhyay reported routine equity compensation and a related share deferral.
Rhea-AI Filing Summary
Vertex Pharmaceuticals director Suketu Upadhyay reported routine equity compensation and a related share deferral. Upon vesting of previously granted restricted stock units, he exchanged 796 shares of common stock for 796 deferred stock units under the company’s deferred compensation plan, recording a disposition to the issuer and a matching derivative acquisition.
He also received a grant of 2,866 stock options exercisable at $424.45 per share, expiring on April 30, 2036. Following these transactions, he holds 1,558 shares of common stock, 3,595.156 deferred stock units, and 2,866 stock options, all reported as direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Upadhyay Suketu
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,866 | $0.00 | $0.00 |
| Grant/Award | Deferred Stock Units | 796 | $0.00 | $0.00 |
| Disposition | Common Stock | 796 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,866 contracts (Direct);
Deferred Stock Units — 3,595.156 contracts (Direct);
Common Stock — 1,558 shares (Direct)
Footnotes (3)
- F1. Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
- F2. Fully vested.
- F3. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.
Key Figures
Common shares disposed to issuer: 796 shares
Deferred stock units granted: 796 units
Stock options granted: 2,866 options
+5 more
8 metrics
Common shares disposed to issuer
796 shares
Exchange for 796 deferred stock units on May 1, 2026
Deferred stock units granted
796 units
One unit represents one share of common stock
Stock options granted
2,866 options
Grant on May 1, 2026, fully vested
Option exercise price
$424.45 per share
Stock Option (Right to Buy) underlying common stock
Option expiration date
April 30, 2036
Expiration of 2,866 stock options
Common shares after transactions
1,558 shares
Directly held common stock following Form 4 entries
Deferred stock units after transactions
3,595.156 units
Balance of deferred stock units after 796-unit grant
Stock options after transactions
2,866 options
Total options reported as directly owned
Key Terms
Deferred Stock Units, Stock Option (Right to Buy), deferred compensation plan, change of control
4 terms
Deferred Stock Units financial
"received instead 796 deferred stock units pursuant to our deferred compensation plan"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security title: Common Stock"
deferred compensation plan financial
"received instead 796 deferred stock units pursuant to our deferred compensation plan"
A deferred compensation plan is an arrangement where an employer agrees to pay part of an employee’s pay or bonus at a later date instead of immediately, often to reduce current tax bills or to tie rewards to long-term performance. For investors it matters because these promises create future cash obligations and influence executive incentives and retention; they can affect a company’s reported liabilities, cash flow planning and the risk profile if the business faces financial trouble.
change of control financial
"upon the earliest to occur of (i) termination ... (ii) a change of control of our company"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Vertex (VRTX) director Suketu Upadhyay report?
Suketu Upadhyay reported exchanging 796 shares of Vertex common stock for 796 deferred stock units and receiving 2,866 stock options. These are compensation and deferral-related entries, not open-market purchases or sales of shares.
How many Vertex (VRTX) stock options were granted to Suketu Upadhyay?
He received 2,866 stock options, each giving the right to buy one Vertex common share at an exercise price of $424.45. These options expire on April 30, 2036, and were reported as fully vested at grant.
What are the terms of Suketu Upadhyay’s deferred stock units in Vertex (VRTX)?
Each deferred stock unit equals one Vertex common share and will be paid in stock upon the earliest of his board service termination, a change of control of the company, or his disability or death, according to the plan description.
What are Suketu Upadhyay’s Vertex (VRTX) holdings after these Form 4 transactions?
After the reported transactions, he holds 1,558 shares of Vertex common stock directly, 3,595.156 deferred stock units, and 2,866 stock options. These positions reflect his reported equity exposure following the compensation and deferral entries.
AI-generated analysis. How Rhea-AI works. Not financial advice.
